Loading...
By Joe Elia
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
Gadolinium contrast agents, which the FDA has warned can accumulate in brain tissue, show no association with parkinsonism risk, a JAMA research letter concludes.
Researchers examined linked provincial databases from Ontario, Canada, to identify nearly a quarter million patients older than 66 years who'd undergone magnetic resonance imaging (not of the brain or spine) at least once between 2003 and 2013. Some 40% received gadolinium.
Parkinsonism developed in 1.17% of those exposed to gadolinium and in 1.16% of those not exposed. Adjustment for covariates, such as sex, comorbid conditions, or medications, did not affect the outcome.
The investigators conclude that their finding "does not support the hypothesis that gadolinium deposits in the globus pallidi lead to neuronal damage manifesting as parkinsonism."
Comment
LINK(S):
JAMA research letter (Subscription required)
Background: Physician's First Watch coverage of 2015 FDA alert on gadolinium contrast agents (Free)